Last updated: August 10, 2026
Nimotop is the original brand of nimodipine, a dihydropyridine calcium-channel blocker used primarily to reduce delayed cerebral ischemia and improve neurologic outcomes after aneurysmal subarachnoid hemorrhage. Its commercial profile is mature: core composition patents and regulatory exclusivity have expired, generic nimodipine is available in several markets, and the product has limited standalone revenue disclosure. Current value depends more on hospital procurement, formulation availability, supply reliability, and clinical protocols than on brand pricing power.
What is Nimotop and how is nimodipine used?
Nimotop contains nimodipine, typically supplied as a 30 mg oral capsule. In the United States, the approved indication is improvement of neurologic outcome by reducing the incidence and severity of ischemic deficits in patients who have experienced subarachnoid hemorrhage from a ruptured intracranial aneurysm, regardless of whether the aneurysm has been surgically repaired [1].
Nimodipine is administered orally or through a feeding tube. Intravenous administration of the capsule contents is unsafe and has been associated with severe hypotension, cardiac arrest, and death. The FDA labeling specifically warns against intravenous or parenteral administration [1].
Clinical market position
The product occupies a narrow neurocritical-care market:
- Primary setting: intensive care and stroke or neurosurgical units.
- Main patient population: patients with aneurysmal subarachnoid hemorrhage.
- Typical treatment duration: 21 consecutive days under U.S. labeling.
- Standard dose: 60 mg every four hours, administered orally or by nasogastric tube.
- Main clinical objective: reduction of delayed cerebral ischemia and improvement in functional neurologic outcome.
The 2023 American Heart Association and American Stroke Association guideline continues to recommend early enteral nimodipine for patients with aneurysmal subarachnoid hemorrhage [2]. This guideline support protects the molecule's clinical relevance even though it does not protect the original brand's pricing.
What is the FDA regulatory status of Nimotop?
Nimotop received U.S. FDA approval under NDA 018869 in 1988. The historical U.S. product was a 30 mg capsule marketed under the Nimotop name. U.S. commercial availability has shifted toward generic nimodipine and alternative branded formulations rather than the original Bayer-branded product.
| Regulatory item |
Status |
| Active ingredient |
Nimodipine |
| U.S. dosage form |
Oral capsule; oral solution products are also available |
| Original U.S. NDA |
NDA 018869 |
| Initial FDA approval |
1988 |
| Approved use |
Neurologic outcome improvement after subarachnoid hemorrhage |
| Administration |
Enteral only |
| Regulatory exclusivity |
Expired |
| Reference product market position |
Mature and largely genericized |
The FDA's historical approval does not mean that the Nimotop brand remains broadly marketed in the United States. Drug discontinuation records can reflect commercial discontinuation rather than withdrawal for safety or lack of efficacy. Generic approval activity and product listings should therefore be separated from brand availability [3].
What patents protect Nimotop?
The original Nimotop patent estate no longer provides meaningful exclusivity in the United States or other major pharmaceutical markets. Nimodipine was discovered and commercialized decades ago, and the basic compound, composition, and original capsule rights have expired.
Patent-expiration profile
| Patent category |
Current commercial relevance |
| Original nimodipine compound patents |
Expired |
| Original capsule formulation patents |
Expired or no longer commercially blocking |
| Regulatory exclusivity |
Expired |
| Core method-of-use rights for subarachnoid hemorrhage |
Expired |
| Modern oral-solution formulation rights |
Potentially separate from Nimotop capsule rights |
| Manufacturing and process patents |
Generally nonblocking for established generic production |
The absence of meaningful core patent protection allows generic manufacturers to enter without a license from Bayer for the original nimodipine capsule product. Patent risk can still arise around later-developed delivery systems, oral solutions, packaging, or manufacturing processes. Those rights would protect a particular product presentation rather than the original Nimotop molecule.
What is the Orange Book status of Nimotop?
The Orange Book is relevant primarily to U.S. approved products and listed patents. The original Nimotop capsule product has no remaining market exclusivity comparable to a new chemical entity, pediatric extension, or active core patent period.
The commercial distinction is important:
- The original Nimotop capsule approval is a legacy reference-product approval.
- Generic nimodipine capsules can compete on an abbreviated new drug application pathway.
- Nymalize, an oral nimodipine solution, is a separate product with separate formulation and labeling considerations.
- Any Orange Book-listed patents associated with an oral solution do not automatically restore exclusivity to Nimotop capsules.
The original product's patent position is therefore weak from a lifecycle-management perspective. The relevant legal question for a generic entrant is usually product-specific patent scope, not whether nimodipine as an active ingredient remains protected.
When did Nimotop lose exclusivity?
Nimotop lost meaningful U.S. exclusivity many years ago. Its 1988 approval predates modern data exclusivity for the product's commercial life, and the original active-ingredient and formulation protections have expired.
Exclusivity timeline
| Period |
Event |
| 1980s |
Nimodipine developed and commercialized |
| 1988 |
FDA approval of Nimotop in the United States |
| 1990s and 2000s |
Core patent and regulatory exclusivity periods expired |
| 2010s |
Additional generic and alternative formulation competition emerged |
| Current market |
Mature generic and hospital-procurement market |
There is no commercially material exclusivity period remaining for the original Nimotop capsule. A new entrant would face regulatory, manufacturing, and distribution barriers, but not a meaningful originator patent barrier.
Which companies compete with Nimotop?
Competition is fragmented by geography and dosage form. Bayer is historically associated with Nimotop, but the U.S. market is now shaped by generic suppliers and alternative nimodipine products.
Main competitive groups
- Generic capsule manufacturers supplying nimodipine 30 mg.
- Manufacturers of oral nimodipine solution, including Nymalize in the United States.
- Regional pharmaceutical companies marketing Nimotop under license or local registration.
- Hospital suppliers that compete through contract pricing, availability, and wholesaler relationships.
Nimodipine has few clinically accepted substitutes for the specific post-subarachnoid-hemorrhage indication. Other calcium-channel blockers are not interchangeable replacements for the guideline-supported use of enteral nimodipine. This reduces therapeutic substitution but does not prevent generic substitution.
How does Nimotop compare with Nymalize?
| Attribute |
Nimotop |
Nymalize |
| Active ingredient |
Nimodipine |
Nimodipine |
| Main dosage form |
30 mg capsule |
Oral solution |
| Primary market role |
Original branded capsule |
Alternative liquid formulation |
| Target users |
Adult neurocritical-care patients |
Patients requiring enteral liquid administration |
| Patent profile |
Legacy, expired core rights |
Potentially distinct formulation rights |
| Commercial differentiation |
Brand recognition and regional availability |
Administration convenience and feeding-tube compatibility |
Nymalize can command a different price because it addresses administration and dosing logistics. Its commercial position is not evidence that Nimotop's core molecule remains protected.
Are there Paragraph IV challenges to Nimotop?
Paragraph IV litigation is not a major current risk to the original Nimotop capsule because the core patent estate is expired or commercially inactive. Generic manufacturers generally do not need to challenge an active composition patent to enter the mature nimodipine capsule market.
The more relevant patent activity concerns later formulations, especially oral solutions. A generic applicant seeking approval for a formulation protected by a listed patent could file a Paragraph IV certification and face Hatch-Waxman litigation. That litigation would concern the formulation patent and the specific reference listed drug, not the historical Nimotop molecule in general.
No widely reported, commercially material current Paragraph IV litigation is associated with the original Nimotop capsule brand. The absence of major litigation is consistent with a mature, low-margin product.
What patent litigation affects Nimotop?
There is no prominent current patent litigation involving the original Nimotop capsule that materially changes market access. The principal legal risks are operational and formulation-specific:
- Product liability arising from incorrect intravenous administration.
- Labeling and medication-error litigation.
- Supply-contract disputes.
- Patent disputes involving oral-solution formulations.
- Regulatory enforcement if a supplier markets an unapproved route or indication.
The route-of-administration warning is commercially important. Hospitals must use an enteral product and maintain handling controls. A formulation that reduces administration errors can obtain procurement advantages even without molecule-level patent protection.
What generic entry risks exist for Nimotop?
Generic entry risk is high because the product is old, clinically established, and exposed to multiple suppliers. The risks are asymmetric:
- Originator downside: continued price erosion and low brand retention.
- Generic upside: modest opportunity for reliable supply and hospital contracts.
- Market risk: limited patient volume and low treatment duration reduce total revenue.
- Manufacturing risk: interruptions can have an outsized impact because neurocritical-care hospitals require continuous access.
- Formulation risk: capsules may be less convenient than oral solutions for intubated or dysphagic patients.
Generic competition does not necessarily eliminate all brand demand. Hospitals may retain a branded or preferred supplier where procurement committees value consistent packaging, established distribution, or product familiarity. That support is usually insufficient to preserve historical brand-level pricing.
What is the financial trajectory for Nimotop?
Standalone Nimotop revenue is not separately disclosed in Bayer's public financial reporting. Bayer reports pharmaceutical performance at broader business-unit levels and does not identify Nimotop as a material individual revenue contributor in its annual reports [4]. A precise global revenue history therefore cannot be established from public company disclosures.
The financial trajectory can be characterized by lifecycle stage:
| Lifecycle stage |
Financial effect |
| Initial launch |
Premium pricing supported by innovation and limited competition |
| Patent-protected period |
Higher margins and stronger distributor leverage |
| Generic entry |
Price erosion and volume migration |
| Mature market |
Low unit economics, tender-based competition, supply-driven share shifts |
| Current stage |
Limited brand revenue, value concentrated in formulation and regional supply |
Revenue exposure
Nimotop is unlikely to be material to Bayer's consolidated revenue. The product's addressable population is narrow, treatment duration is limited, and the molecule has been genericized for years. Revenue exposure is more relevant to small generic manufacturers and specialty hospital suppliers than to the historical originator.
Commercial value may still exist in markets where:
- Nimotop remains the recognized hospital brand.
- Generic registration is limited.
- Local tender systems favor established suppliers.
- Oral formulations are difficult to source.
- Physicians and hospitals maintain protocol preference for a known product.
Public sources do not provide a reliable standalone global sales figure for Nimotop. Market-research estimates should be treated as product-category estimates unless they identify audited brand sales.
How strong is the Nimotop patent estate?
The original Nimotop patent estate is weak for current market defense.
| Strength factor |
Assessment |
| Core molecule protection |
None remaining |
| Original capsule protection |
Expired |
| Regulatory exclusivity |
None remaining |
| Brand recognition |
Still meaningful in some markets |
| Clinical guideline support |
Strong for the labeled neurocritical-care use |
| Generic barriers |
Low to moderate |
| Manufacturing complexity |
Relatively low |
| Supply-chain value |
Moderate |
| Pricing power |
Low |
The product has clinical durability but limited legal exclusivity. Its strongest defenses are guideline adoption, hospital familiarity, supply reliability, and formulation availability.
What manufacturing and intellectual-property barriers remain?
Nimodipine is a small molecule and does not present biologic manufacturing complexity. There is no biosimilar pathway because biosimilars apply to biological products, not small-molecule nimodipine. Generic applicants generally use the abbreviated new drug application pathway in the United States.
Remaining barriers include:
- Demonstrating pharmaceutical equivalence and bioequivalence.
- Establishing stable product quality.
- Controlling impurity profiles and dissolution performance.
- Maintaining compliant oral or enteral packaging.
- Supporting reliable hospital distribution.
- Managing medication-error risks caused by improper administration.
For oral solutions, manufacturing and packaging may be more demanding than for capsules. Concentration accuracy, container closure, dosing devices, and enteral-tube compatibility can create practical differentiation.
What licensing deals affect Nimotop?
Bayer historically commercialized Nimotop through its international pharmaceutical operations and regional distribution arrangements. Current public disclosures do not identify a major, active global licensing transaction that materially changes the product's economics.
Regional rights may vary by country. Brand ownership, marketing authorization ownership, local distributor status, and manufacturing rights should not be treated as identical. In mature pharmaceutical markets, commercial arrangements may consist of ordinary supply, distribution, or local marketing agreements rather than high-value strategic licensing transactions.
What generic launch scenarios are most likely?
The original capsule market supports three likely commercial scenarios.
Continued commoditization
Generic suppliers maintain access, prices remain compressed, and brand sales continue to decline. This is the baseline scenario in the United States and other markets with multiple approved suppliers.
Supplier consolidation
One or two manufacturers gain share because hospitals prioritize continuity of supply. Prices may stabilize temporarily, but the market remains vulnerable to a new entrant or procurement rebid.
Formulation migration
Hospitals shift some use from capsules to oral solution where feeding-tube administration, swallowing difficulty, or dosing logistics favor a liquid product. This creates formulation-level competition rather than a new molecule market.
Key Takeaways
- Nimotop is the original brand of nimodipine, approved for neurologic outcome improvement after aneurysmal subarachnoid hemorrhage.
- FDA approval dates to 1988, and core patent and regulatory exclusivity have expired.
- The original Nimotop capsule has little current patent-based market protection.
- Generic nimodipine is the principal source of U.S. competition.
- Nymalize and other oral-solution products compete through formulation and administration convenience.
- No biosimilar risk exists because nimodipine is a small molecule.
- Current financial exposure is difficult to quantify because Bayer does not separately report Nimotop revenue.
- The product's value rests on clinical guideline support, hospital protocol adoption, supply reliability, and formulation access.
- Current litigation risk is more likely to involve later formulations, labeling, or supply than the original molecule.
- Generic launch risk is high, while originator pricing power is low.
FAQs
Is Nimotop still sold in the United States?
The original branded Nimotop capsule has a limited U.S. commercial role. U.S. treatment access is primarily supported by generic nimodipine and alternative approved formulations.
Is nimodipine still recommended after subarachnoid hemorrhage?
Yes. Current U.S. stroke guidance recommends early enteral nimodipine for patients with aneurysmal subarachnoid hemorrhage [2].
Can generic nimodipine replace Nimotop?
Approved generic nimodipine can generally substitute for the capsule reference product, subject to formulary, availability, and prescribing requirements. Oral solution products are not automatically interchangeable with capsules in every procurement or regulatory context.
Does Nimotop have biologic or biosimilar competition?
No. Nimodipine is a chemically synthesized small molecule. Competing products are generics or alternative formulations, not biosimilars.
What is the main commercial opportunity in the nimodipine market?
The most defensible opportunities are reliable hospital supply, regional registration, oral-solution delivery, and formulations designed for enteral administration. The original capsule molecule offers limited opportunity for premium pricing or patent-based exclusivity.
References
-
U.S. Food and Drug Administration. (2018). Nimodipine prescribing information. FDA/DailyMed.
-
Hoh, B. L., Ko, N. U., Amin-Hanjani, S., Chou, S. H.-Y., Cousins, S. E., et al. (2023). 2023 guideline for the management of patients with aneurysmal subarachnoid hemorrhage. Stroke, 54(7), e314-e370.
-
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.
-
Bayer AG. (2024). Annual report 2023. Bayer AG.
